Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lucien Maria Henricus Koymans is active.

Publication


Featured researches published by Lucien Maria Henricus Koymans.


Talanta | 2005

Improving QSAR models for the biological activity of HIV Reverse Transcriptase inhibitors: Aspects of outlier detection and uninformative variable elimination

M. Daszykowski; I. Stanimirova; B. Walczak; Frits Daeyaert; M.R. de Jonge; Jan Heeres; Lucien Maria Henricus Koymans; Paulus Joannes Lewi; Hendrik Maarten Vinkers; Paul A. J. Janssen; D.L. Massart

The goal of this study is to derive a methodology for modeling the biological activity of non-nucleoside HIV Reverse Transcriptase (RT) inhibitors. The difficulties that were encountered during the modeling attempts are discussed, together with their origin and solutions. With the selected multivariate techniques: robust principal component analysis, partial least squares, robust partial least squares and uninformative variable elimination partial least squares, it is possible to explore and to model the contaminated data satisfactory. It is shown that these techniques are versatile and valuable tools in modeling and exploring biochemical data.


Journal of Computer-aided Molecular Design | 2003

Inhibition and substrate recognition: a computational approach applied to HIV protease

Hendrik Maarten Vinkers; M.R. de Jonge; Frits Daeyaert; Jan Heeres; Lucien Maria Henricus Koymans; J.H. van Lenthe; Paulus Joannes Lewi; H. Timmerman; Paul A. J. Janssen

We have developed a computational approach in which an inhibitors strength is determined from its interaction energy with a limited set of amino acid residues of the inhibited protein. We applied this method to HIV protease. The method uses a consensus structure built from X-ray crystallographic data. All inhibitors are docked into the consensus structure. Given that not every ligand–protein interaction causes inhibition, we implemented a genetic algorithm to determine the relevant set of residues. The algorithm optimizes the q2 between the sum of interaction energies and the observed inhibition constants. The best possible predictive model resulting has a q2 of 0.63. External validation by examining the predictivity for compounds not used in derivation of the model leads to a prediction accuracy between 0.9 and 1.5 log10 unit. Out of 198 residues in the whole protein, the best internally predictive model defines a subset of 20 residues and the best externally predictive model one of 9 residues. These residues are distributed over the subsites of the enzyme. This approach provides insight in which interactions are important for inhibiting HIV protease and it allows for quantitative prediction of inhibitor strength.


Archive | 2002

Hiv inhibiting pyrimidines derivatives

Jérôme Emile Georges Guillemont; Patrice Palandjian; Marc René De Jonge; Lucien Maria Henricus Koymans; Hendrik Maarten Vinkers; Frederik Frans Desiré Daeyaert; Jan Heeres; Koen Jeanne Alfons Van Aken; Paulus Joannes Lewi; Paul A. J. Janssen


Archive | 1999

HIV inhibiting pyrimidine derivatives

Koenraad Jozef Lodewijk Marcel Andries; Corte Bart De; Jonge Marc Rene De; Jan Heeres; Chih Yung Ho; Marcel Janssen; Paul A. J. Janssen; Lucien Maria Henricus Koymans; Michael Joseph Kukla; Donald William Ludovici; Aken Koen Jeanne Alfons Van


Archive | 1999

Hiv replication inhibiting pyrimidines

Bart De Corte; Marc René De Jonge; Jan Heeres; Chih Yung Ho; Paul A. J. Janssen; Robert W. Kavash; Lucien Maria Henricus Koymans; Michael Joseph Kukla; Donald William Ludovici; Koen Jeanne Alfons Van Aken


Archive | 2002

Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)

Eddy Jean Edgard Freyne; Peter Jacobus Johannes Antonius Buijnsters; Marc Willems; Werner Constant Johan Embrechts; Christopher John Love; Paul A. J. Janssen; Paulus Joannes Lewi; Jan Heeres; Marc René De Jonge; Lucien Maria Henricus Koymans; Hendrik Maarten Vinkers; Koen Jeanne Alfons Van Aken; Gaston Stanislas Marcella Diels


Archive | 2001

HIV replication inhibitors

Michael Joseph Kukla; Donald William Ludovici; Robert W. Kavash; Bart De Corte; Jan Heeres; Paul A. J. Janssen; Lucien Maria Henricus Koymans; Marc René De Jonge; Koen Jeanne Alfons Van Aken; Alain Krief; Ruben Gerardus George Leenders


Archive | 2004

Pyrimidine derivatives for the prevention of HIV infection

Jan Heeres; Paulus Joannes Lewi; Jonge Marc Rene De; Lucien Maria Henricus Koymans; Frederik Frans Desiré Daeyaert; Hendrik Maarten Vinkers; Jérôme Emile Georges Guillemont; Elisabeth Thérèse Jeanne Pasquier; Paul A. J. Janssen


Archive | 2002

Amide derivatives as glycogen synthase kinase 3-beta inhibitors

Eddy Jean Edgard Freyne; Peter Jacobus Johannes Antonius Buijnsters; Marc Willems; Werner Constant Johan Embrechts; Jean Fernand Armand Lacrampe; Paul A. J. Janssen; Herwig Josephus Margareta Janssen; Paul Peter Maria Janssen; Graziella Maria Constantina Janssen; Jasmine Josee Werner Janssen; Maroussia Godelieve Frank Janssen; Theodora Joanna Francisca Arts; Paulus Joannes Lewi; Jan Heeres; Marc René De Jonge; Lucien Maria Henricus Koymans; Frederik Frans Desiré Daeyaert; Rony Nuydens; Marc Mercken


Archive | 1999

HIV inhibiting pyrimidine derivative

Koenraad Jozef Lodewijk Marcel Andries; Bart De Corte; Marc René De Jonge; Jan Heeres; Chih Yung Ho; Marcel Janssen; Paul A. J. Janssen; Lucien Maria Henricus Koymans; Michael Joseph Kukla; Donald William Ludovici; Koen Jeanne Alfons Van Aken

Collaboration


Dive into the Lucien Maria Henricus Koymans's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge